Retension Pharmaceuticals, Inc.

S-1 filed

Retension Pharmaceuticals, Inc. is advancing its lead candidate, RTN-001, through clinical development, with a focus on its Phase 2b trial initiated in October 2025. The company faces significant risks in clinical and preclinical development, including uncertainty in trial outcomes, regulatory delays, and reliance on third-party manufacturers and CROs. Financially, the company expects proceeds from this offering to fund operations through the next [X] months but acknowledges the need for additional capital. It has assumed royalty obligations under the Redux Agreement, adding to its financial commitments. The filing emphasizes the high failure rates in biopharmaceutical development and the potential for setbacks despite prior results.

DRS/A amended

Retension Pharmaceuticals, Inc. details its reliance on third-party manufacturers for RTN-001 production and commercialization, emphasizing cost efficiency and focus on R&D. The company projects funding runway through the next [X] months using offering proceeds and existing cash, but warns of capital exhaustion risks. It assumes royalty obligations under the Redux Agreement, including low-teens percentages on sales and sublicensing. R&D and general & administrative expenses surged in 2026 due to Phase 2b trial costs, expanded operations, and public company readiness. Financials show increased losses, with restatements for accounting errors in 2025.

DRS/A amended

DRS/A amended

Retension Pharmaceuticals, Inc. is a clinical-stage biotech company focused on developing treatments for hypertension and cardiovascular diseases. The company reported significant financial growth in 2025, with total assets increasing to $19.1M from $8.4M in 2024. Key changes include the introduction of Series B convertible preferred stock, expanded R&D expenses, and a larger accumulated deficit. The company remains dependent on external financing to sustain operations and achieve regulatory approvals for its pipeline.

DRS filed

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hypertension and cardiovascular disease. The company, incorporated in July 2023, has raised capital through Series A convertible preferred stock issuances and reports recurring net losses, negative cash flows from operations, and an accumulated deficit of approximately $2 million as of December 2024. The financial statements, audited by Wolf & Company, P.C., reflect growth in assets and liabilities, with $8.19 million in cash and cash equivalents as of December 31, 2024. The company faces risks related to FDA approval timelines, liquidity constraints, and dependence on key personnel and additional financing.